Prescriptions for success
Competitive strategies for Canada’s biopharmaceutical companies
As Canada’s population ages, health care budgets spiral out of control. With the trend only set to accelerate, our governments — and citizens — are increasingly turning to biopharmaceuticals for solutions. Yet international competition for R&D investment is putting Canada’s biopharmaceutical companies behind the eight ball, ultimately inhibiting them from reaching their full potential.
The challenges facing the biopharmaceutical industry include extended timelines for bringing products to market, tightening pricing regulations and a growing concern over protection of intellectual property. The lack of financial liquidity is also a critical challenge. But Canada’s biopharmaceutical sector can reposition itself to attract much-needed financing by adopting global best practices.
Take the lead examines some of these best practices in the context of current industry challenges. It also proposes action steps biopharmaceutical players can take to make themselves more attractive to global R&D investors. This Deloitte Life Sciences publication will help you gain a better understanding of the opportunities available to Canada’s biopharmaceutical companies, benchmark against leading global practices, and identify strategies for improvement.
Page Last Updated